Methods of treating acute coronary syndromes

Patent metadata

Field	Value
Publication number	US-12558365-B2
Application number	US-202017438712-A
Country	US
Kind code	B2
Filing date	Mar 12, 2020
Priority date	Mar 13, 2019
Publication date	Feb 24, 2026
Grant date	Feb 24, 2026

Abstract

The invention provides methods for treating and preventing acute coronary syndromes (ACS). The methods involve initiation of the administration of glucose-insulin-potassium (GIK) soon (e.g., within 3 hours) after the onset of ACS symptoms.

First claim

The invention claimed is:

1 . A method of treating, inhibiting, or preventing acute coronary syndromes (ACS) in a patient, the method comprising initiating the administration of a solution of glucose-insulin-potassium (GIK) to the patient within one hour or less of ACS symptom onset.

2 . The method of claim 1 , further comprising assessment by emergency medical service personnel.

3 . The method of claim 1 , wherein the administration of GIK is initiated upon assessment in (a) the emergency department (ED), (b) the hospital upon cardiac arrest, (c) a medical office setting, or (d) under the care of paramedics in the community.

4 . The method of claim 1 , wherein the patient has or is at risk of developing one or more ACS symptom selected from the group consisting of: chest pain, angina, radiating pain from the chest to the shoulders, arms, upper abdomen, back, neck, or jaw; nausea or vomiting; indigestion; shortness of breath; heavy sweating; lightheadedness; dizziness; fainting; unusual or unexplained fatigue; and feeling restless or apprehensive.

5 . The method of claim 1 , wherein the patient experiences an improvement in progression to myocardial infarction, 30-day survival, in-hospital mortality, or cardiac arrest due to the GIK treatment.

6 . The method of claim 1 , wherein the patient experiences a significant clinical improvement, or a group of patients experiences a statistically significant improvement, with respect to 30-day survival, 30-day heart failure, or in-hospital cardiac arrest.

7 . The method of claim 1 , wherein the patient is further treated with aspirin, P2Y 12 receptor antagonist, anticoagulant, beta blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blocker, fibrinolytic agent, statin, morphine, nitroglycerin, oxygen, interventional angioplasty, surgery or any combination thereof.

8 . The method of claim 1 , wherein the GIK comprises 25-35% glucose, 45-55 U/l regular insulin, and 70-90 mEq potassium chloride per liter.

9 . The method of claim 8 , wherein the GIK comprises 30% glucose, 50 U/l regular insulin, and 80 mEq of potassium chloride per liter.

10 . The method of claim 1 , wherein the GIK is administered at a speed of 1 to 2 ml/kg/hour for 10-14 hours.

11 . The method of claim 10 , wherein the GIK is administered at a speed of 1.5 ml/kg/hour for 12 hours.

12 . A method of treating, inhibiting, or preventing acute coronary syndromes (ACS) in a patient, the method comprising initiating the administration of a solution of glucose-insulin-potassium (GIK) to the patient within 3 to 6 hours of ACS symptom onset.

13 . The method of claim 12 , further comprising assessment by emergency medical service personnel.

14 . The method of claim 12 , wherein the administration of GIK is initiated upon assessment in (a) the emergency department (ED), (b) the hospital upon cardiac arrest, (c) a medical office setting, or (d) under the care of paramedics in the community.

15 . The method of claim 12 , wherein the patient has or is at risk of developing one or more ACS symptom selected from the group consisting of: chest pain, angina, radiating pain from the chest to the shoulders, arms, upper abdomen, back, neck, or jaw; nausea or vomiting; indigestion; shortness of breath; heavy sweating; lightheadedness; dizziness; fainting; unusual or unexplained fatigue; and feeling restless or apprehensive.

16 . The method of claim 12 , wherein the patient experiences an improvement in progression to myocardial infarction, 30-day survival, in-hospital mortality, or cardiac arrest due to the GIK treatment.

17 . The method of claim 12 , wherein the patient experiences a significant clinical improvement, or a group of patients experiences a statistically significant improvement, with respect to 30-day survival, 30-day heart failure, or in-hospital cardiac arrest.

18 . The method of claim 12 , wherein the patient is further treated with aspirin, P2Y 12 receptor antagonist, anticoagulant, beta blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blocker, fibrinolytic agent, statin, morphine, nitroglycerin, oxygen, interventional angioplasty, surgery or any combination thereof.

19 . The method of claim 12 , wherein the GIK comprises 25-35% glucose, 45-55 U/l regular insulin, and 70-90 mEq potassium chloride per liter.

20 . The method of claim 19 , wherein the GIK comprises 30% glucose, 50 U/l regular insulin, and 80 m Eq of potassium chloride per liter.

21 . The method of claim 12 , wherein the GIK is administered at a speed of 1 to 2 ml/kg/hour for 10-14 hours.

22 . The method of claim 21 , wherein the GIK is administered at a speed of 1.5 ml/kg/hour for 12 hours.

Assignees

• Tufts Medical Ct Inc

Inventors

• Selker Harry

Classifications

• A61K38/28

  Insulins · CPC title

• A61K33/14

  Alkali metal chlorides; Alkaline earth metal chlorides · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61K31/7004 Primary

  Monosaccharides having only carbon, hydrogen and oxygen atoms · CPC title

• A61K45/06 Primary

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title